上颌窦鳞状细胞癌不同治疗方式的临床疗效及预后分析

目的:探讨49例上颌窦鳞状细胞癌患者的临床疗效并分析生存率.方法:回顾性分析2000年1月至2012年1月收治的49例上颌窦鳞状细胞癌患者临床资料,分别比较单纯手术+术后放疗组患者和诱导化疗+手术+术后放疗组的5年生存率.这些病例(5年内死亡病例随访至死亡日)均随访5年以上,无1例失访.结果:49例病例资料中,随访率为100.0％.5年中29例患者死亡,总生存率为40.8％(20/49),单纯手术+术后放疗者23例,死亡患者15例,生存率为34.8％(8/23);诱导化疗+手术+术后放疗者26例,死亡患者14例,生存率为46.2％ (12/26),两组生存率比较,差异有统计学意义(P＜0.05).结论:上颌窦鳞状细胞癌主要的死亡原因与临床分期及术后复发转移密切相关,以手术为主的综合治疗有益于上颌窦鳞状细胞癌疗效的提高,控制局部瘤体病变及预防术后复发是影响上颌窦鳞状细胞癌疗效的关键.

Clinical efficiency and prognosis analysis on different treatment modes of maxillary sinus squamous cell carcinoma

Objective:To discuss the treating effect and the related factors which influenced the prognosis of the maxillary sinus squamous cell carcinoma.Methods:The 49 cases clinical data of maxillary sinus squamous cell carcinoma patients from January 2000 to January 2012 were retrospectively analyzed,then the relationship among those underwent different treatment through comparing the 5 years survival rate of each treating group was observed.All the ca ses underwent follow-up for 5 years,no case lost.Results:Among the 49 cases,the follow-up rate was 100.0％.23 cases underwent the operating treatment combined with postoperative radiotherapy,26 cases underwent the preoperative induction chemotherapy combined with the operating treatment and postoperative radiotherapy.29 cases died in 5 years and the overall 5-year survival rate was 40.8％.There were 16 cases died in 5 years in the operating treatment combined with radiotherapy group,the 5 years survival rate was 34.8％.There were 14 cases died in 5 years in the preoperative induction chemotherapy + operating treatment + postoperative radiotherapy group,the 5-year survival rate was 46.2％ (P ＜ 0.05).Conclusion:The main cause of death in maxillary sinus squamous cell carcinoma is closely relevant to clinical stages or the postoperative recurrence and metastasis.Surgery-based comprehensive treatment is conductive to the treating effect improvement for the maxillary sinus squamous cell carcinoma.Control of local tumor disease and prevent postoperative recurrence are the key to the efficacy of maxillary sinus squamous cell cancer.